Skip to main content

Advertisement

SpringerLink
Log in

[18F]-FMISO PET study of hypoxia in gliomas before surgery: correlation with molecular markers of hypoxia and angiogenesis

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

Hypoxia in gliomas is associated with tumor resistance to radio- and chemotherapy. However, positron emission tomography (PET) imaging of hypoxia remains challenging, and the validation of biological markers is, therefore, of great importance. We investigated the relationship between uptake of the PET hypoxia tracer [18F]-FMISO and other markers of hypoxia and angiogenesis and with patient survival.

Patients and methods

In this prospective single center clinical study, 33 glioma patients (grade IV: n = 24, III: n = 3, and II: n = 6) underwent [18F]-FMISO PET and MRI including relative cerebral blood volume (rCBV) maps before surgery. Maximum standardized uptake values (SUVmax) and hypoxic volume were calculated, defining two groups of patients based on the presence or absence of [18F]-FMISO uptake. After surgery, molecular quantification of CAIX, VEGF, Ang2 (rt-qPCR), and HIF-1α (immunohistochemistry) were performed on tumor specimens.

Results

[18F]-FMISO PET uptake was closely linked to tumor grade, with high uptake in glioblastomas (GB, grade IV). Expression of biomarkers of hypoxia (CAIX, HIF-1α), and angiogenesis markers (VEGF, Ang2, rCBV) were significantly higher in the [18F]-FMISO uptake group. We found correlations between the degree of hypoxia (hypoxic volume and SUVmax) and expression of HIF-1α, CAIX, VEGF, Ang2, and rCBV (p < 0.01). Patients without [18F]-FMISO uptake had a longer survival time than uptake positive patients (log-rank, p < 0.005).

Conclusions

Tumor hypoxia as evaluated by [18F]-FMISO PET is associated with the expression of hypoxia markers on a molecular level and is related to angiogenesis. [18F]-FMISO uptake is a mark of an aggressive tumor, almost always a glioblastoma. Our results underline that [18F]-FMISO PET could be useful to guide glioma treatment, and in particular radiotherapy, since hypoxia is a well-known factor of resistance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Rampling R, Cruickshank G, Lewis AD, Fitzsimmons SA, Workman P. Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys. 1994;29(3):427–31.

    Article  CAS  PubMed  Google Scholar 

  2. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Evans SM, Judy KD, Dunphy I, et al. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res. 2004;10(24):8177–84.

    Article  CAS  PubMed  Google Scholar 

  4. Evans SM, Jenkins KW, Chen HI, et al. The relationship among hypoxia, proliferation, and outcome in patients with de novo glioblastoma: a pilot study. Transl Oncol. 2010;3(3):160–9.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Szeto MD, Chakraborty G, Hadley J, et al. Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. Cancer Res. 2009;69(10):4502–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Brown JM. Therapeutic targets in radiotherapy. Int J Radiat Oncol Biol Phys. 2001;49(2):319–26.

    Article  CAS  PubMed  Google Scholar 

  7. Hall EJ, Giaccia AJ. Radiobiology for the radiologist. 7th ed. Philadelphia: LWW; 2011. 576p.

    Google Scholar 

  8. Flynn JR, Wang L, Gillespie DL, et al. Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme. Cancer. 2008;113(5):1032–42.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Spence AM, Muzi M, Swanson KR, et al. Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res. 2008;14(9):2623–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Corroyer-Dulmont A, Chakhoyan A, Collet S, et al. Imaging modalities to assess oxygen status in glioblastoma. Front Med. 2015. doi:10.3389/fmed.2015.00057.

    Google Scholar 

  11. Chen W, Silverman DHS. Advances in evaluation of primary brain tumors. Semin Nucl Med. 2008;38(4):240–50.

    Article  PubMed  Google Scholar 

  12. Derlon JM, Chapon F, Noël MH, et al. Non-invasive grading of oligodendrogliomas: correlation between in vivo metabolic pattern and histopathology. Eur J Nucl Med. 2000;27(7):778–87.

    Article  CAS  PubMed  Google Scholar 

  13. Collet S, Valable S, Constans JM, et al. [(18)F]-fluoro-L-thymidine PET and advanced MRI for preoperative grading of gliomas. Neuroimage Clin. 2015;8:448–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Valk PE, Mathis CA, Prados MD, Gilbert JC, Budinger TF. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med. 1992;33:2133–7.

    CAS  PubMed  Google Scholar 

  15. Cher LM, Murone C, Lawrentschuk N, et al. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. J Nucl Med. 2006;47(3):410–8.

    CAS  PubMed  Google Scholar 

  16. Lee ST, Scott AM. Hypoxia positron emission tomography imaging with 18f-fluoromisonidazole. Semin Nucl Med. 2007;37(6):451–61.

    Article  PubMed  Google Scholar 

  17. Koh WJ, Rasey JS, Evans ML, et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys. 1992;22(1):199–212.

    Article  CAS  PubMed  Google Scholar 

  18. Rasey JS, Koh WJ, Evans ML, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys. 1996;36(2):417–28.

    Article  CAS  PubMed  Google Scholar 

  19. Bernsen HJ, Rijken PF, Peters H, et al. Hypoxia in a human intracerebral glioma model. J Neurosurg. 2000;93(3):449–54.

    Article  CAS  PubMed  Google Scholar 

  20. Sharp FR, Bernaudin M. HIF1 and oxygen sensing in the brain. Nat Rev Neurosci. 2004;5(6):437–48.

    Article  CAS  PubMed  Google Scholar 

  21. Harris AL. Hypoxia, a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2(1):38–47.

    Article  CAS  PubMed  Google Scholar 

  22. Denko NC, Fontana LA, Hudson KM, et al. Investigating hypoxic tumor physiology through gene expression patterns. Oncogene. 2003;22(37):5907–14.

    Article  CAS  PubMed  Google Scholar 

  23. Said HM, Hagemann C, Staab A, et al. Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo. Radiother Oncol. 2007;83(3):398–405.

    Article  CAS  PubMed  Google Scholar 

  24. Pastorek J, Pastorekova S. Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: from biology to clinical use. Semin Cancer Biol. 2015;31:52–64.

    Article  CAS  PubMed  Google Scholar 

  25. Fagiani E, Christofori G. Angiopoietins in angiogenesis. Cancer Lett. 2013;328(1):18–26.

    Article  CAS  PubMed  Google Scholar 

  26. Bruehlmeier M, Roelcke U, Schubiger PA, Ametamey SM. Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O. J Nucl Med. 2004;45(11):1851–9.

    PubMed  Google Scholar 

  27. Yamamoto Y, Maeda Y, Kawai N, et al. Hypoxia assessed by 18F-fluoromisonidazole positron emission tomography in newly diagnosed gliomas. Nucl Med Commun. 2012;33(6):621–5.

    Article  CAS  PubMed  Google Scholar 

  28. Kawai N, Lin W, Cao W-D, et al. Correlation between 18F-fluoromisonidazole PET and expression of HIF-1α and VEGF in newly diagnosed and recurrent malignant gliomas. Eur J Nucl Med Mol Imaging. 2014;41(10):1870–8.

    Article  CAS  PubMed  Google Scholar 

  29. Chang CW, Chou TK, Liu RS, et al. A robotic synthesis of [18F]fluoromisonidazole ([18F]FMISO). Appl Radiat Isot. 2007;65(6):682–6.

    Article  CAS  PubMed  Google Scholar 

  30. Valable S, Petit E, Roussel S, et al. Complementary information from magnetic resonance imaging and (18)F-fluoromisonidazole positron emission tomography in the assessment of the response to an antiangiogenic treatment in a rat brain tumor model. Nucl Med Biol. 2011;38(6):781–93.

    CAS  PubMed  Google Scholar 

  31. Swanson KR, Chakraborty G, Wang CH, et al. Complementary but distinct roles for MRI and 18F-Fluoromisonidazole PET in the assessment of human glioblastomas. J Nucl Med. 2009;50(1):36–44.

    Article  PubMed  Google Scholar 

  32. Yasui H, Matsumoto S, Devasahayam N, et al. Low-field magnetic resonance imaging to visualize chronic and cycling hypoxia in tumor-bearing mice. Cancer Res. 2010;70(16):6427–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Gerstner ER, Zhang Z, Fink JR, et al. ACRIN 6684: assessment of tumor hypoxia in newly diagnosed glioblastoma using 18F-FMISO PET and MRI. Clin Cancer Res. 2016;22(20):5079–86.

    Article  CAS  PubMed  Google Scholar 

  34. Vartanian A, Singh SK, Agnihotri S, et al. GBM’s multifaceted landscape: highlighting regional and microenvironmental heterogeneity. Neuro-Oncology. 2014;16(9):1167–75.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Bell C, Dowson N, Fay M, et al. Hypoxia imaging in gliomas with 18F-fluoromisonidazole PET: toward clinical translation. Semin Nucl Med. 2015;45(2):136–50.

    Article  PubMed  Google Scholar 

  36. Hirata K, Terasaka S, Shiga T, et al. 18F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas. Eur J Nucl Med Mol Imaging. 2012;39(5):760–70.

    Article  CAS  PubMed  Google Scholar 

  37. Toyonaga T, Yamaguchi S, Hirata K, et al. Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor. Eur J Nucl Med Mol Imaging. 2016. doi:10.1371/journal.pone.0167917.

    Google Scholar 

Download references

Acknowledgements

We thank neurosurgeons S. Khoury, B. Gadan, A. Borha. We also thank S. de Bouard, J. Pierre, S. Lecot-Cotigny and N. Elie. We thank V. Constans and S. Kabani for editing the manuscript.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author information

Authors and Affiliations

  1. Department of Neurology, CHU de Caen, Caen, France

    Lien Bekaert, Pierre Branger & Jean-Sébastien Guillamo

  2. Normandie Univ, UNICAEN, CEA, CNRS, ISTCT/CERVOxy group, 14000, Caen, France

    Lien Bekaert, Samuel Valable, Emmanuèle Lechapt-Zalcman, Keven Ponte, Solène Collet, Jean-Marc Constans, Karim Bordji, Edwige Petit, Myriam Bernaudin & Jean-Sébastien Guillamo

  3. Department of Neurosurgery, CHU de Caen, Caen, France

    Lien Bekaert, Keven Ponte & Evelyne Emery

  4. Service de Neurochirurgie, CHU de Caen, Avenue de la Côte de Nacre, 14000, Caen, France

    Lien Bekaert

  5. Department of Pathology, CHU de Caen, Caen, France

    Emmanuèle Lechapt-Zalcman & Guénaëlle Levallet

  6. Department of Neuroradiology, CHU de Caen, Caen, France

    Jean-Marc Constans

  7. Department of Nuclear Medicine, CHU de Caen, Caen, France

    Alain Manrique

  8. Normandie Univ, UNICAEN, CEA, CNRS, ISTCT/LDM-TEP group, 14000, Caen, France

    Louisa Barré

  9. Department of Neurology, CHU de Nimes, Place du Professeur Robert Debre, 30029, Nimes cedex 9, France

    Jean-Sébastien Guillamo

Authors
  1. Lien Bekaert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Samuel Valable
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Emmanuèle Lechapt-Zalcman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Keven Ponte
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Solène Collet
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jean-Marc Constans
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Guénaëlle Levallet
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Karim Bordji
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Edwige Petit
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Pierre Branger
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Evelyne Emery
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Alain Manrique
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Louisa Barré
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Myriam Bernaudin
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Jean-Sébastien Guillamo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Lien Bekaert or Jean-Sébastien Guillamo.

Ethics declarations

Funding

This study was funded by Centre National de la Recherche Scientifique (CNRS), Université de Caen Normandie (UCN), Conseil Régional de Basse-Normandie (CRBN) and Institut National du Cancer (INCa).

Conflict of interest

None of the authors have a conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bekaert, L., Valable, S., Lechapt-Zalcman, E. et al. [18F]-FMISO PET study of hypoxia in gliomas before surgery: correlation with molecular markers of hypoxia and angiogenesis. Eur J Nucl Med Mol Imaging 44, 1383–1392 (2017). https://doi.org/10.1007/s00259-017-3677-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-017-3677-5

Keywords

Search

Navigation